Curis, Inc. announced a private placement totaling up to $80.8 million in gross proceeds.
The PIPE financing involves new and existing healthcare-focused, high-quality institutional investors and certain insiders of the Company.
The financing is expected to close on or about January 8, 2026, subject to customary closing conditions.
Private Placement Details
Curis, Inc. is selling 20,195 shares of Series B convertible non-redeemable preferred stock and various warrants to investors.
Investor Participation
The placement includes new and existing healthcare-focused institutional investors, insiders of the Company, and the Company's executive team.
Use of Proceeds
The company intends to use the proceeds for research and development, general corporate expenses, and working capital needs.
- The PIPE financing is crucial for Curis, Inc. to fund its ongoing research efforts and operational requirements.
- This funding will support the development of emavusertib (CA-4948), a significant focus for the biotechnology company.
The successful pricing of the private placement demonstrates investor confidence in Curis, Inc.'s growth prospects and strategic initiatives.